Efficacy and Safety Evaluation of Immune Checkpoint Inhibitors in Combination With Chemotherapy for Extensive Small Cell Lung Cancer: Real‐World Evidence
2024

Efficacy and Safety of Immune Checkpoint Inhibitors with Chemotherapy for Small Cell Lung Cancer

Sample size: 100 publication 10 minutes Evidence: moderate

Author Information

Author(s): Yuta Yamanaka, Yukiko Okuno, Keisuke Kamisako, Yuta Okazaki, Kentaro Nakanishi, Yume Sanada, Kiyori Yoshida, Tatsuki Ikoma, Yuki Takeyasu, Utae Katsushima, Hiroshige Yoshioka, Takayasu Kurata

Primary Institution: Kansai Medical University Hospital

Hypothesis

Understanding the effectiveness of immune checkpoint inhibitors in different patient populations will affect future prognostic outcomes.

Conclusion

The IMpower133 regimen appears more effective in patients with brain metastasis compared to the CASPIAN regimen.

Supporting Evidence

  • The IMpower133 regimen showed a median OS of 13.43 months.
  • The CASPIAN regimen showed a median OS of 10.6 months.
  • Patients with brain metastasis treated with IMpower133 had significantly better outcomes.
  • Statistical analysis indicated no significant differences in PFS and OS between the two regimens overall.
  • Adverse events were reported more frequently in the CASPIAN group.

Takeaway

This study looked at how well two treatments work for lung cancer that has spread, finding one treatment is better for patients with brain problems.

Methodology

Retrospective analysis of treatment data from patients diagnosed with extensive small cell lung cancer who received immune checkpoint inhibitors as first-line chemotherapy.

Potential Biases

Potential biases due to reliance on physician-reported adverse events and the retrospective design.

Limitations

The retrospective nature of the study introduced various biases, and there was a discrepancy in the number of cases between the treatment groups.

Participant Demographics

Median age was 74.5 years for the IMpower133 group and 76.0 years for the CASPIAN group, with no significant difference in sex ratio.

Statistical Information

P-Value

p=0.629 for PFS; p=0.348 for OS

Confidence Interval

95% CI for PFS: 4.43–5.53 months; 95% CI for OS: 10.97–17.77 months

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1002/cam4.70480

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication